Form 4: KalVista Pharmaceuticals Director Acquires Stock Options
SEC Form 4 Filing
William Fairey, a director of KalVista Pharmaceuticals, acquired stock options for 10,000 shares on October 3, 2024.
Summary
- On October 3, 2024, William Fairey, a director at KalVista Pharmaceuticals, acquired stock options for 10,000 shares of common stock.
- The options have an exercise price of $11.54.
- The options vest monthly over a 12-month period, starting November 3, 2024, and expire on October 2, 2034.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing related to stock option grants, and doesn't inherently indicate positive or negative sentiment. It simply reflects insider activity.
Industry Context
This is a standard Form 4 filing, indicating a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the trading activities of company directors and officers.
Stakeholder Impact
- The acquisition of stock options by a director could be perceived positively by shareholders, as it aligns the director's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 10/03/2024 | Date of stock option acquisition |
| 11/03/2024 | First vesting date of the stock options (1/12th) |
| 10/02/2034 | Expiration date of the stock options |
| 10/04/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.